BDBM494874 4-((17-(4-(4-(4-((2-chlorobenzyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-6-yl)benzyl)piperazin-1-yl)-3,6,9,12,15-pentaoxaheptadecyl)amino)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione::US10994015, Example 8

SMILES O=C1CCC(N2C(=O)c3cccc(NCCOCCOCCOCCOCCOCCN4CCN(Cc5ccc(-c6cc7c(NCc8ccccc8Cl)ncnc7[nH]6)cc5)CC4)c3C2=O)C(=O)N1

InChI Key InChIKey=IWNRQWVSRJPEDL-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 494874   

LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 1.70nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor [L858R](Human)
Arvinas

US Patent
LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 11nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Arvinas

US Patent
LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 89nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetEpidermal growth factor receptor(Human)
Arvinas

US Patent
LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 450nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

TargetReceptor tyrosine-protein kinase erbB-2(Human)
Arvinas

US Patent
LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 1.20E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 3.20E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 4.80E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent

LigandChemical structure of BindingDB Monomer ID 494874BDBM494874(US10994015, Example 8 | 4-((17-(4-(4-(4-((2-chloro...)
Affinity DataIC50: 7.20E+3nMAssay Description:All compounds and PROTACs were serially diluted in three-fold increments using 100% DMSO, followed by an intermediate 10-fold dilution using Buffer A...More data for this Ligand-Target Pair
In Depth
Date in BDB:
11/4/2021
Entry Details
US Patent